-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-516741-39-00
6
2020-01-14
Haemophilia A
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-512104-19-00
6
2019-11-19
Irritable Bowel Syndrome
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-513526-27-00
4
2018-02-23
secondary or quaternary peritonitis
-
2024-511988-29-01
3
2017-11-08
Glioblastoma
-
2024-517236-22-00
5
2017-09-20
Intradural saccular unruptured aneurysm
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-514556-32-00
5
2017-02-15
Adult critically ill patients with severe vitamin D deficiency
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-521918-26-00
4
2026-02-11
HIV Infections
-
2024-517757-27-00
6
2026-01-29
Hereditary Angioedema (HAE)
-
2025-521912-21-00
4
2026-01-26
Cardiovascular risk reduction in participants with elevated Lp(a)
-
2025-520775-81-00
5
2025-12-23
Short Bowel Syndrome
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-519469-23-00
4
2025-10-20
Severe Asthma
-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema